Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Analysts estimate that Albertsons Companies will report an earnings per share (EPS) of $0.52. Investors in Albertsons ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report ...

Our Top 5 Analyst Questions Pfizer’s Q1 Earnings Call Vamil Divan (Guggenheim): Asked about Pfizer’s ability to maintain and grow its dividend amid tariff uncertainty and cash flow pressure.

Pfizer (PFE) ended the recent trading session at $25.35, demonstrating a -1.17% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 0.14%.

Pfizer's revenue slump is temporary. New launches and Seagen integration drive 2025 growth. Read here for an investment analysis of PFE stock.

Pfizer's cost-cutting boosts earnings despite revenue miss. Discover its growth strategy, strong drug portfolio & potential 29% upside. Click here to read.

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Pfizer PFE is likely to encounter several headwinds in the next couple of years that can hurt its sales and profits, the first being declining sales of COVID products, Comirnaty and Paxlovid.